ID   ASIC1_RAT               Reviewed;         526 AA.
AC   P55926; O88762; Q91YB8; Q99NA1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   02-OCT-2024, entry version 177.
DE   RecName: Full=Acid-sensing ion channel 1 {ECO:0000303|PubMed:9062189};
DE            Short=ASIC1 {ECO:0000303|PubMed:9062189};
DE   AltName: Full=Amiloride-sensitive cation channel 2, neuronal;
DE   AltName: Full=Brain sodium channel 2;
DE            Short=BNaC2;
GN   Name=Asic1; Synonyms=Accn2, Bnac2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   ACTIVITY REGULATION.
RX   PubMed=9062189; DOI=10.1038/386173a0;
RA   Waldmann R., Champigny G., Bassilana F., Heurteaux C., Lazdunski M.;
RT   "A proton-gated cation channel involved in acid-sensing.";
RL   Nature 386:173-177(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Spinal ganglion;
RX   PubMed=9707631; DOI=10.1073/pnas.95.17.10240;
RA   Chen C.-C., England S., Akopian A.N., Wood J.N.;
RT   "A sensory neuron-specific, proton-gated ion channel.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10240-10245(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), DOMAIN, AND FUNCTION.
RC   TISSUE=Inner ear;
RX   PubMed=11448963; DOI=10.1074/jbc.m104030200;
RA   Baessler E.-L., Ngo-Anh T.J., Geisler H.-S., Ruppersberg J.P., Gruender S.;
RT   "Molecular and functional characterization of acid-sensing ion channel
RT   (ASIC) 1b.";
RL   J. Biol. Chem. 276:33782-33787(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND FUNCTION.
RC   TISSUE=Trigeminal ganglion;
RX   PubMed=11588592; DOI=10.1097/00001756-200109170-00022;
RA   Ugawa S., Ueda T., Takahashi E., Hirabayashi Y., Yoneda T., Komai S.,
RA   Shimada S.;
RT   "Cloning and functional expression of ASIC-beta2, a splice variant of ASIC-
RT   beta.";
RL   NeuroReport 12:2865-2869(2001).
RN   [5]
RP   TISSUE SPECIFICITY, INTERACTION WITH ASIC1, MUTAGENESIS OF GLY-431, AND
RP   FUNCTION.
RX   PubMed=9360943; DOI=10.1074/jbc.272.46.28819;
RA   Bassilana F., Champigny G., Waldmann R., de Weille J.R., Heurteaux C.,
RA   Lazdunski M.;
RT   "The acid-sensitive ionic channel subunit ASIC and the mammalian degenerin
RT   MDEG form a heteromultimeric H+-gated Na+ channel with novel properties.";
RL   J. Biol. Chem. 272:28819-28822(1997).
RN   [6]
RP   INTERACTION WITH THE SPIDER VENOM PSALMOTOXIN-1 TOXIN, AND SUBUNIT.
RX   PubMed=10829030; DOI=10.1074/jbc.m003643200;
RA   Escoubas P., de Weille J.R., Lecoq A., Diochot S., Waldmann R.,
RA   Champigny G., Moinier D., Menez A., Lazdunski M.;
RT   "Isolation of a tarantula toxin specific for a class of proton-gated Na+
RT   channels.";
RL   J. Biol. Chem. 275:25116-25121(2000).
RN   [7]
RP   REGULATION BY FMRFAMIDE-RELATED PEPTIDES.
RX   PubMed=10798398; DOI=10.1016/s0896-6273(00)81144-7;
RA   Askwith C.C., Cheng C., Ikuma M., Benson C., Price M.P., Welsh M.J.;
RT   "Neuropeptide FF and FMRFamide potentiate acid-evoked currents from sensory
RT   neurons and proton-gated DEG/ENaC channels.";
RL   Neuron 26:133-141(2000).
RN   [8]
RP   INDUCTION, AND INHIBITION BY DRUGS.
RX   PubMed=11588175; DOI=10.1523/jneurosci.21-20-08026.2001;
RA   Voilley N., de Weille J.R., Mamet J., Lazdunski M.;
RT   "Nonsteroid anti-inflammatory drugs inhibit both the activity and the
RT   inflammation-induced expression of acid-sensing ion channels in
RT   nociceptors.";
RL   J. Neurosci. 21:8026-8033(2001).
RN   [9]
RP   MUTAGENESIS OF PHE-100; VAL-103; LYS-105 AND ASN-106, AND FUNCTION.
RX   PubMed=12198124; DOI=10.1074/jbc.m205877200;
RA   Babini E., Paukert M., Geisler H.-S., Gruender S.;
RT   "Alternative splicing and interaction with di- and polyvalent cations
RT   control the dynamic range of acid-sensing ion channel 1 (ASIC1).";
RL   J. Biol. Chem. 277:41597-41603(2002).
RN   [10]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=11842212; DOI=10.1073/pnas.042688199;
RA   Alvarez de la Rosa D., Zhang P., Shao D., White F., Canessa C.M.;
RT   "Functional implications of the localization and activity of acid-sensitive
RT   channels in rat peripheral nervous system.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:2326-2331(2002).
RN   [11]
RP   MUTAGENESIS OF SER-83; GLN-84; LEU-85 AND 128-GLN--ASP-131.
RX   PubMed=12947112; DOI=10.1074/jbc.m304441200;
RA   Coric T., Zhang P., Todorovic N., Canessa C.M.;
RT   "The extracellular domain determines the kinetics of desensitization in
RT   acid-sensitive ion channel 1.";
RL   J. Biol. Chem. 278:45240-45247(2003).
RN   [12]
RP   FUNCTION.
RX   PubMed=15369669; DOI=10.1016/j.cell.2004.08.026;
RA   Xiong Z.-G., Zhu X.-M., Chu X.-P., Minami M., Hey J., Wei W.-L.,
RA   MacDonald J.F., Wemmie J.A., Price M.P., Welsh M.J., Simon R.P.;
RT   "Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion
RT   channels.";
RL   Cell 118:687-698(2004).
RN   [13]
RP   MUTAGENESIS OF GLU-425; ASP-432 AND GLN-436.
RX   PubMed=15452199; DOI=10.1085/jgp.200308973;
RA   Paukert M., Babini E., Pusch M., Grunder S.;
RT   "Identification of the Ca2+ blocking site of acid-sensing ion channel
RT   (ASIC) 1: implications for channel gating.";
RL   J. Gen. Physiol. 124:383-394(2004).
RN   [14]
RP   INTERACTION WITH SNAKE VENOM MAMBALGIN-1 AND MAMBALGIN-2, AND SUBUNIT.
RC   TISSUE=Venom, and Venom gland;
RX   PubMed=23034652; DOI=10.1038/nature11494;
RA   Diochot S., Baron A., Salinas M., Douguet D., Scarzello S.,
RA   Dabert-Gay A.-S., Debayle D., Friend V., Alloui A., Lazdunski M.,
RA   Lingueglia E.;
RT   "Black mamba venom peptides target acid-sensing ion channels to abolish
RT   pain.";
RL   Nature 490:552-555(2012).
RN   [15]
RP   INTERACTION WITH MAMBALGIN-1; MAMBALGIN-2 AND MAMBALGIN-3, SUBUNIT, AND
RP   REVIEW.
RX   PubMed=23624383; DOI=10.1016/j.toxicon.2013.04.008;
RA   Baron A., Diochot S., Salinas M., Deval E., Noel J., Lingueglia E.;
RT   "Venom toxins in the exploration of molecular, physiological and
RT   pathophysiological functions of acid-sensing ion channels.";
RL   Toxicon 75:187-204(2013).
RN   [16]
RP   MUTAGENESIS OF PHE-350, INTERACTION WITH MAMBALGIN-2, AND SUBUNIT.
RX   PubMed=24323786; DOI=10.1002/anie.201308898;
RA   Schroeder C.I., Rash L.D., Vila-Farres X., Rosengren K.J., Mobli M.,
RA   King G.F., Alewood P.F., Craik D.J., Durek T.;
RT   "Chemical synthesis, 3D structure, and ASIC binding site of the toxin
RT   mambalgin-2.";
RL   Angew. Chem. Int. Ed. 53:1017-1020(2014).
RN   [17]
RP   MUTAGENESIS OF ARG-190; 259-ASP-GLN-260; 349-ASP-PHE-350; ASP-349; PHE-350;
RP   VAL-352; GLN-356 AND GLU-357, INTERACTION WITH MAMBALGIN-2, AND SUBUNIT.
RX   PubMed=24695733; DOI=10.1074/jbc.m114.561076;
RA   Salinas M., Besson T., Delettre Q., Diochot S., Boulakirba S., Douguet D.,
RA   Lingueglia E.;
RT   "Binding site and inhibitory mechanism of the mambalgin-2 pain-relieving
RT   peptide on acid-sensing ion channel 1a.";
RL   J. Biol. Chem. 289:13363-13373(2014).
RN   [18]
RP   MUTAGENESIS OF GLU-235; TYR-316; PHE-350 AND LYS-354, INTERACTION WITH THE
RP   SPIDER VENOM PSALMOTOXIN-1 TOXIN, AND SUBUNIT.
RX   PubMed=26248594; DOI=10.1111/bph.13267;
RA   Saez N.J., Deplazes E., Cristofori-Armstrong B., Chassagnon I.R., Lin X.,
RA   Mobli M., Mark A.E., Rash L.D., King G.F.;
RT   "Molecular dynamics and functional studies define a hot spot of crystal
RT   contacts essential for psalmotoxin-1 inhibition of acid-sensing ion channel
RT   1a.";
RL   Br. J. Pharmacol. 172:4985-4995(2015).
RN   [19]
RP   MUTAGENESIS OF PHE-350, INTERACTION WITH MAMBALGIN-1, AND SUBUNIT.
RX   PubMed=26680001; DOI=10.1074/jbc.m115.702373;
RA   Mourier G., Salinas M., Kessler P., Stura E.A., Leblanc M., Tepshi L.,
RA   Besson T., Diochot S., Baron A., Douguet D., Lingueglia E., Servent D.;
RT   "Mambalgin-1 pain-relieving peptide, stepwise solid-phase synthesis,
RT   crystal structure, and functional domain for acid-sensing ion channel 1a
RT   inhibition.";
RL   J. Biol. Chem. 291:2616-2629(2016).
RN   [20]
RP   MUTAGENESIS OF HIS-173; PHE-174; ARG-175; GLU-177; ALA-178 AND PHE-350,
RP   INTERACTION WITH THE SPIDER VENOM PI-THERAPHOTOXIN-HM3A, AND SUBUNIT.
RC   TISSUE=Venom;
RX   PubMed=28327374; DOI=10.1016/j.neuropharm.2017.03.020;
RA   Er S.Y., Cristofori-Armstrong B., Escoubas P., Rash L.D.;
RT   "Discovery and molecular interaction studies of a highly stable, tarantula
RT   peptide modulator of acid-sensing ion channel 1.";
RL   Neuropharmacology 114:3750-3755(2017).
RN   [21]
RP   MUTAGENESIS OF PHE-350, INTERACTION WITH THE SPIDER PI-HEXATOXIN-HI1A, AND
RP   SUBUNIT.
RX   PubMed=28320941; DOI=10.1073/pnas.1614728114;
RA   Chassagnon I.R., McCarthy C.A., Chin Y.K., Pineda S.S., Keramidas A.,
RA   Mobli M., Pham V., De Silva T.M., Lynch J.W., Widdop R.E., Rash L.D.,
RA   King G.F.;
RT   "Potent neuroprotection after stroke afforded by a double-knot spider-venom
RT   peptide that inhibits acid-sensing ion channel 1a.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3750-3755(2017).
CC   -!- FUNCTION: Proton-gated sodium channel; it is activated by a drop of the
CC       extracellular pH and then becomes rapidly desensitized. Generates a
CC       biphasic current with a fast inactivating and a slow sustained phase.
CC       Has high selectivity for sodium ions and can also transport lithium
CC       ions with high efficiency. Can also transport potassium ions, but with
CC       lower efficiency. It is nearly impermeable to the larger rubidium and
CC       cesium ions. Isoform 3 discrimates stronger than isoform 1 between
CC       monovalent cations. Isoform 3 can flux Ca(2+) while isoform 1 cannot.
CC       Heteromeric channels composed of isoform 2 and isoform 3 are active but
CC       have a lower pH-sensitivity. Mediates glutamate-independent Ca(2+)
CC       entry into neurons upon acidosis. This Ca(2+) overloading is toxic for
CC       cortical neurons and may be in part responsible for ischemic brain
CC       injury. Heteromeric channel assembly seems to modulate channel
CC       properties. {ECO:0000269|PubMed:11448963, ECO:0000269|PubMed:11588592,
CC       ECO:0000269|PubMed:12198124, ECO:0000269|PubMed:15369669,
CC       ECO:0000269|PubMed:9062189, ECO:0000269|PubMed:9360943,
CC       ECO:0000269|PubMed:9707631}.
CC   -!- ACTIVITY REGULATION: Inhibited by the diuretic amiloride.
CC       {ECO:0000269|PubMed:9062189}.
CC   -!- SUBUNIT: Homotrimer or heterotrimer with other ASIC proteins (By
CC       similarity). Interacts with STOM and PRKCABP (By similarity). Interacts
CC       with ASIC2. Interacts with the spider venom Pi-hexatoxin-Hi1a
CC       (PubMed:28320941). Homotrimer of Asic1a interacts with the spider venom
CC       psalmotoxin-1 (PubMed:10829030, PubMed:26248594). Homotrimer of Asic1a
CC       (isoform 1) and Asic1b (isoform 3) and heterotrimer of Asic1a/Asic1b
CC       interact with the spider venom Pi-theraphotoxin-Hm3a (PubMed:28327374).
CC       Homotrimer of Asic1a (ASIC1 isoform 1) interacts with the snake venom
CC       mambalgin-1, mambalgin-2 and mambalgin-3 (PubMed:23034652,
CC       PubMed:23624383, PubMed:24323786, PubMed:24695733, PubMed:26680001).
CC       Homotrimer of Asic1b (isoform 3) interacts with the snake venom
CC       mambalgin-1, mambalgin-2 and mambalgin-3 (PubMed:23034652,
CC       PubMed:23624383, PubMed:24323786, PubMed:26680001). Heterotrimer of
CC       Asic1a-Asic1b (ASIC1 isoform 1-ASIC1 isoform 3) interacts with the
CC       snake venom mambalgin-1 and mambalgin-2 (PubMed:23034652). Heterotrimer
CC       of Asic1a-Asic2a interacts with the snake venom mambalgin-1, mambalgin-
CC       2 and mambalgin-3 (PubMed:23034652, PubMed:23624383, PubMed:26680001).
CC       Heterotrimer of Asic1a-Asic2b (ASIC1 isoform 1-ASIC2 isoform 2)
CC       interacts with the snake venom mambalgin-1 and mambalgin-2
CC       (PubMed:23034652). {ECO:0000250, ECO:0000269|PubMed:10829030,
CC       ECO:0000269|PubMed:23034652, ECO:0000269|PubMed:23624383,
CC       ECO:0000269|PubMed:24323786, ECO:0000269|PubMed:24695733,
CC       ECO:0000269|PubMed:26248594, ECO:0000269|PubMed:26680001,
CC       ECO:0000269|PubMed:28320941, ECO:0000269|PubMed:28327374,
CC       ECO:0000269|PubMed:9360943}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11842212,
CC       ECO:0000269|PubMed:9062189, ECO:0000269|PubMed:9707631}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:11842212,
CC       ECO:0000269|PubMed:9062189, ECO:0000269|PubMed:9707631}. Note=Localizes
CC       in synaptosomes at dendritic synapses of neurons. Colocalizes with DLG4
CC       (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=ASIC-alpha, asic1alpha, ASIC1a
CC       {ECO:0000303|PubMed:11448963};
CC         IsoId=P55926-1; Sequence=Displayed;
CC       Name=2; Synonyms=ASIC-beta2;
CC         IsoId=P55926-2; Sequence=VSP_015597, VSP_015598;
CC       Name=3; Synonyms=ASIC-beta, ASIC1b {ECO:0000303|PubMed:11448963};
CC         IsoId=P55926-3; Sequence=VSP_015597, VSP_015599;
CC   -!- TISSUE SPECIFICITY: Expressed in dorsal root ganglia and sciatic nerve
CC       (at protein level). Widely distributed throughout the brain. Expressed
CC       in olfactory bulb, neo and allocortical regions, dentate granule cells,
CC       pyramidal cells of CA1-CA3 subfields of the hippocampal formation,
CC       habenula, basolateral amygdaloid nuclei, and in the Purkinje and
CC       granule cells of the cerebellum. Diffusely detected over most other
CC       regions of the basal ganglia, including thalamic nuclei, substantia
CC       nigra, striatum and globus pallidus, hypothalamus, midbrain, pons,
CC       medulla and choroid plexus. Isoform 3 is expressed only in dorsal root
CC       ganglion (DRG) while isoform 1 is expressed in DRG, spinal chord,
CC       trigeminal ganglia and the trigeminal mesencephalic nucleus.
CC       {ECO:0000269|PubMed:11588592, ECO:0000269|PubMed:11842212,
CC       ECO:0000269|PubMed:9360943, ECO:0000269|PubMed:9707631}.
CC   -!- INDUCTION: Up-regulation upon tissues inflammation is abolished by
CC       anti-inflammatory drugs. {ECO:0000269|PubMed:11588175}.
CC   -!- DOMAIN: Channel opening involves a conformation change that affects
CC       primarily the extracellular domain and the second transmembrane helix
CC       and its orientation in the membrane. In the open state, the second
CC       transmembrane helix is nearly perpendicular to the plane of the
CC       membrane; in the desensitized state it is strongly tilted. Besides, the
CC       second transmembrane domain is discontinuously helical in the open
CC       state. The GAS motif of the selectivity filter is in an extended
CC       conformation, giving rise to a distinct kink in the polypeptide chain.
CC       A domain swap between subunits gives rise to a full-length
CC       transmembrane helix (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylation by PKA regulates interaction with PRKCABP and
CC       subcellular location. Phosphorylation by PKC may regulate the channel
CC       (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: Potentiated by Ca(2+), Mg(2+), Ba(2+), multivalent
CC       cations and potentiated by FMRFamide-related neuropeptides. pH
CC       dependence may be regulated by serine proteases. Inhibited by anti-
CC       inflammatory drugs like salicylic acid. Isoform 1 homomultimeric
CC       channel is specifically and reversibly inhibited by psalmotoxin-1, a
CC       spider venom toxin, while isoform 2 and other ASICs are insensitive.
CC   -!- MISCELLANEOUS: [Isoform 2]: Inactive. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Blocked by Ca(2+). Mutagenesis of Asp-465
CC       to Asn reduces Ca(2+) block. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the amiloride-sensitive sodium channel (TC
CC       1.A.6) family. ASIC1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA07080.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- SEQUENCE CAUTION: [Isoform 3]:
CC       Sequence=CAA07080.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U94403; AAB53002.1; -; mRNA.
DR   EMBL; AJ006519; CAA07080.1; ALT_FRAME; mRNA.
DR   EMBL; AJ309926; CAC44267.1; -; mRNA.
DR   EMBL; AB049451; BAB39864.1; -; mRNA.
DR   RefSeq; NP_077068.1; NM_024154.2. [P55926-1]
DR   RefSeq; XP_006257440.1; XM_006257378.3. [P55926-3]
DR   AlphaFoldDB; P55926; -.
DR   SMR; P55926; -.
DR   MINT; P55926; -.
DR   STRING; 10116.ENSRNOP00000068902; -.
DR   BindingDB; P55926; -.
DR   ChEMBL; CHEMBL3562170; -.
DR   DrugCentral; P55926; -.
DR   GuidetoPHARMACOLOGY; 684; -.
DR   TCDB; 1.A.6.1.2; the epithelial na(+) channel (enac) family.
DR   GlyCosmos; P55926; 2 sites, No reported glycans.
DR   GlyGen; P55926; 2 sites.
DR   iPTMnet; P55926; -.
DR   PhosphoSitePlus; P55926; -.
DR   SwissPalm; P55926; -.
DR   ABCD; P55926; 1 sequenced antibody.
DR   Ensembl; ENSRNOT00000077175.2; ENSRNOP00000072206.2; ENSRNOG00000059765.2. [P55926-3]
DR   Ensembl; ENSRNOT00055050447; ENSRNOP00055041531; ENSRNOG00055029116. [P55926-1]
DR   Ensembl; ENSRNOT00060010923; ENSRNOP00060008130; ENSRNOG00060006660. [P55926-1]
DR   Ensembl; ENSRNOT00065039196; ENSRNOP00065031840; ENSRNOG00065022925. [P55926-1]
DR   GeneID; 79123; -.
DR   KEGG; rno:79123; -.
DR   AGR; RGD:71062; -.
DR   CTD; 41; -.
DR   RGD; 71062; Asic1.
DR   VEuPathDB; HostDB:ENSRNOG00000059765; -.
DR   GeneTree; ENSGT00940000158414; -.
DR   HOGENOM; CLU_020415_1_2_1; -.
DR   InParanoid; P55926; -.
DR   OrthoDB; 3415680at2759; -.
DR   PhylomeDB; P55926; -.
DR   TreeFam; TF330663; -.
DR   Reactome; R-RNO-2672351; Stimuli-sensing channels.
DR   PRO; PR:P55926; -.
DR   Proteomes; UP000002494; Chromosome 7.
DR   Bgee; ENSRNOG00000059765; Expressed in cerebellum and 16 other cell types or tissues.
DR   ExpressionAtlas; P55926; baseline and differential.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0098839; C:postsynaptic density membrane; ISO:RGD.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0045202; C:synapse; ISO:RGD.
DR   GO; GO:0022890; F:inorganic cation transmembrane transporter activity; IDA:MGI.
DR   GO; GO:0015280; F:ligand-gated sodium channel activity; IBA:GO_Central.
DR   GO; GO:0005261; F:monoatomic cation channel activity; ISO:RGD.
DR   GO; GO:0005216; F:monoatomic ion channel activity; IDA:RGD.
DR   GO; GO:0022839; F:monoatomic ion-gated channel activity; ISO:RGD.
DR   GO; GO:0160128; F:pH-gated monoatomic ion channel activity; IDA:UniProtKB.
DR   GO; GO:0008306; P:associative learning; ISO:RGD.
DR   GO; GO:0001662; P:behavioral fear response; ISO:RGD.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; ISO:RGD.
DR   GO; GO:0071467; P:cellular response to pH; ISS:UniProtKB.
DR   GO; GO:0051649; P:establishment of localization in cell; ISO:RGD.
DR   GO; GO:0098662; P:inorganic cation transmembrane transport; IDA:MGI.
DR   GO; GO:0007613; P:memory; ISO:RGD.
DR   GO; GO:0006812; P:monoatomic cation transport; ISO:RGD.
DR   GO; GO:0034220; P:monoatomic ion transmembrane transport; IMP:RGD.
DR   GO; GO:0046929; P:negative regulation of neurotransmitter secretion; ISO:RGD.
DR   GO; GO:0007269; P:neurotransmitter secretion; ISO:RGD.
DR   GO; GO:0070207; P:protein homotrimerization; ISS:UniProtKB.
DR   GO; GO:0042391; P:regulation of membrane potential; ISO:RGD.
DR   GO; GO:0150052; P:regulation of postsynapse assembly; ISO:RGD.
DR   GO; GO:0010447; P:response to acidic pH; ISO:RGD.
DR   GO; GO:0001975; P:response to amphetamine; ISO:RGD.
DR   GO; GO:0050915; P:sensory perception of sour taste; ISO:RGD.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; ISS:UniProtKB.
DR   Gene3D; 1.10.3590.10; acid-sensing ion channel 1 domain; 2.
DR   Gene3D; 1.10.287.820; Acid-sensing ion channel domain; 1.
DR   Gene3D; 1.10.287.770; YojJ-like; 2.
DR   InterPro; IPR001873; ENaC.
DR   InterPro; IPR004724; ENaC_chordates.
DR   InterPro; IPR020903; ENaC_CS.
DR   NCBIfam; TIGR00859; ENaC; 1.
DR   PANTHER; PTHR11690:SF170; ACID-SENSING ION CHANNEL 1; 1.
DR   PANTHER; PTHR11690; AMILORIDE-SENSITIVE SODIUM CHANNEL-RELATED; 1.
DR   Pfam; PF00858; ASC; 1.
DR   PRINTS; PR01078; AMINACHANNEL.
DR   PROSITE; PS01206; ASC; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Calcium transport; Cell membrane;
KW   Disulfide bond; Glycoprotein; Ion channel; Ion transport; Membrane;
KW   Phosphoprotein; Reference proteome; Sodium; Sodium channel;
KW   Sodium transport; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..526
FT                   /note="Acid-sensing ion channel 1"
FT                   /id="PRO_0000181300"
FT   TOPO_DOM        1..45
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        46..69
FT                   /note="Helical"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        70..425
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        426..452
FT                   /note="Discontinuously helical"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        453..526
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          20..25
FT                   /note="Involved in divalent cations permeability"
FT   MOTIF           442..444
FT                   /note="Selectivity filter"
FT                   /evidence="ECO:0000305"
FT   SITE            71
FT                   /note="Important for channel gating"
FT                   /evidence="ECO:0000250"
FT   SITE            79
FT                   /note="Important for channel desensitizing"
FT                   /evidence="ECO:0000250"
FT   SITE            175
FT                   /note="Important residue in interaction with the spider
FT                   venom Pi-theraphotoxin-Hm3a, which can explain functional
FT                   difference between ASIC1a and ASIC1b"
FT                   /evidence="ECO:0000269|PubMed:28327374"
FT   SITE            177
FT                   /note="Important residue for interaction with the spider
FT                   venom Pi-theraphotoxin-Hm3a, which can explain functional
FT                   difference between ASIC1a and ASIC1b"
FT                   /evidence="ECO:0000269|PubMed:28327374"
FT   SITE            287
FT                   /note="Important for channel gating"
FT                   /evidence="ECO:0000250"
FT   SITE            349
FT                   /note="Important for interaction with the snake venom
FT                   mambalgin-2"
FT                   /evidence="ECO:0000269|PubMed:24695733"
FT   SITE            350
FT                   /note="Important for interaction with the snake venom
FT                   mambalgin-1 and mambalgin-2 toxins, probably binds to its
FT                   residue L-53; Important for interaction with the spider
FT                   venom Pi-hexatoxin-Hi1a and psalmotoxin-1"
FT                   /evidence="ECO:0000269|PubMed:24323786,
FT                   ECO:0000269|PubMed:24695733, ECO:0000269|PubMed:26248594,
FT                   ECO:0000269|PubMed:26680001, ECO:0000269|PubMed:28320941"
FT   MOD_RES         477
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P78348"
FT   MOD_RES         497
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6NXK8"
FT   CARBOHYD        366
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        393
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        93..194
FT                   /evidence="ECO:0000250|UniProtKB:Q1XA76"
FT   DISULFID        172..179
FT                   /evidence="ECO:0000250|UniProtKB:Q1XA76"
FT   DISULFID        290..365
FT                   /evidence="ECO:0000250|UniProtKB:Q1XA76"
FT   DISULFID        308..361
FT                   /evidence="ECO:0000250|UniProtKB:Q1XA76"
FT   DISULFID        312..359
FT                   /evidence="ECO:0000250|UniProtKB:Q1XA76"
FT   DISULFID        321..343
FT                   /evidence="ECO:0000250|UniProtKB:Q1XA76"
FT   DISULFID        323..335
FT                   /evidence="ECO:0000250|UniProtKB:Q1XA76"
FT   VAR_SEQ         1..185
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11448963,
FT                   ECO:0000303|PubMed:11588592, ECO:0000303|PubMed:9707631"
FT                   /id="VSP_015597"
FT   VAR_SEQ         186
FT                   /note="V -> MADIWGPHHHRQQQDSSESEEEEEKEMEAGSELDEGDDSPRDLVAFA
FT                   NSCTLHGASHVFVEGGPGPRQALWAVAFVIALGAFLCQ (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11588592"
FT                   /id="VSP_015598"
FT   VAR_SEQ         186
FT                   /note="V -> MPIQIFCSVSFSSGEEAPGSMADIWGPHHHRQQQDSSESEEEEEKEM
FT                   EAGSELDEGDDSPRDLVAFANSCTLHGASHVFVEGGPGPRQALWAVAFVIALGAFLCQV
FT                   GDRVAYYLSYPHVTLLDEVATTELVFPAVTFCNTNAVRLSQLSYPDLLYLAPMLGLDES
FT                   DDPGVPLAPPGPEAFSGEPFNLHRFYNRSCHRLEDMLLYCSYCGGPCGPHNFSV (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11448963,
FT                   ECO:0000303|PubMed:9707631"
FT                   /id="VSP_015599"
FT   MUTAGEN         83
FT                   /note="S->P: No effect. Increases desensitization rates;
FT                   when associated with L-84 and M-85."
FT                   /evidence="ECO:0000269|PubMed:12947112"
FT   MUTAGEN         84
FT                   /note="Q->L: No effect. Increases desensitization rates;
FT                   when associated with P-83 and M-85."
FT                   /evidence="ECO:0000269|PubMed:12947112"
FT   MUTAGEN         85
FT                   /note="L->M: No effect. Increases desensitization rates;
FT                   when associated with P-83 and L-84."
FT                   /evidence="ECO:0000269|PubMed:12947112"
FT   MUTAGEN         100
FT                   /note="F->L: No effect on channel activation and
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:12198124"
FT   MUTAGEN         103
FT                   /note="V->L: No effect on channel activation and
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:12198124"
FT   MUTAGEN         105
FT                   /note="K->Y: Activated and inactivated at lower pH."
FT                   /evidence="ECO:0000269|PubMed:12198124"
FT   MUTAGEN         106
FT                   /note="N->P: Activated and inactivated at lower pH."
FT                   /evidence="ECO:0000269|PubMed:12198124"
FT   MUTAGEN         128..131
FT                   /note="QMAD->HLVE: No effect on desensitization rates."
FT                   /evidence="ECO:0000269|PubMed:12947112"
FT   MUTAGEN         173
FT                   /note="H->S: No significant decrease in inhibition by the
FT                   spider pi-theraphotoxin-Hm3a."
FT                   /evidence="ECO:0000269|PubMed:28327374"
FT   MUTAGEN         174
FT                   /note="F->Y: No significant decrease in inhibition by the
FT                   spider pi-theraphotoxin-Hm3a."
FT                   /evidence="ECO:0000269|PubMed:28327374"
FT   MUTAGEN         175
FT                   /note="R->C: 18-fold decrease in inhibition by the spider
FT                   pi-theraphotoxin-Hm3a."
FT                   /evidence="ECO:0000269|PubMed:28327374"
FT   MUTAGEN         177
FT                   /note="E->G: 10-fold decrease in inhibition by the spider
FT                   pi-theraphotoxin-Hm3a."
FT                   /evidence="ECO:0000269|PubMed:28327374"
FT   MUTAGEN         178
FT                   /note="A->P: No significant decrease in inhibition by the
FT                   spider pi-theraphotoxin-Hm3a."
FT                   /evidence="ECO:0000269|PubMed:28327374"
FT   MUTAGEN         178
FT                   /note="A->V: No significant decrease in inhibition by the
FT                   spider pi-theraphotoxin-Hm3a."
FT                   /evidence="ECO:0000269|PubMed:28327374"
FT   MUTAGEN         190
FT                   /note="R->K: Small decrease in inhibition by the snake
FT                   mambalgin-2 toxin; RDQ-KQE mutant."
FT                   /evidence="ECO:0000269|PubMed:24695733"
FT   MUTAGEN         235
FT                   /note="E->A: No change in the shift of pH for both
FT                   activation and desensitization by the spider venom
FT                   psalmotoxin-1."
FT                   /evidence="ECO:0000269|PubMed:26248594"
FT   MUTAGEN         259..260
FT                   /note="DQ->QE: Small decrease in inhibition by the snake
FT                   mambalgin-2 toxin; RDQ-KQE mutant."
FT                   /evidence="ECO:0000269|PubMed:24695733"
FT   MUTAGEN         316
FT                   /note="Y->A: No change in the shift of pH for both
FT                   activation and desensitization by the spider venom
FT                   psalmotoxin-1."
FT                   /evidence="ECO:0000269|PubMed:26248594"
FT   MUTAGEN         349..350
FT                   /note="DF->GL: Complete loss in inhibition by 200 nM of the
FT                   snake mambalgin-2 toxin."
FT                   /evidence="ECO:0000269|PubMed:24695733"
FT   MUTAGEN         349
FT                   /note="D->G: High decrease in inhibition by the snake
FT                   mambalgin-2 toxin."
FT                   /evidence="ECO:0000269|PubMed:24695733"
FT   MUTAGEN         350
FT                   /note="F->A: Complete loss of inhibition by the spider Pi-
FT                   hexatoxin-Hi1a, and by the snake mambalgin-2 toxin.
FT                   Potentiated by the spider pi-theraphotoxin-Hm3a (at both pH
FT                   7.35 and 7.45) and inhibited at higher toxin concentration
FT                   at pH 7.35. Complete loss in the shift of pH for both
FT                   activation and desensitization by the spider venom
FT                   psalmotoxin-1."
FT                   /evidence="ECO:0000269|PubMed:24323786,
FT                   ECO:0000269|PubMed:26248594, ECO:0000269|PubMed:28320941,
FT                   ECO:0000269|PubMed:28327374"
FT   MUTAGEN         350
FT                   /note="F->L: 37-fold decrease in inhibition by the snake
FT                   mambalgin-1 toxin. Very high decrease in inhibition by the
FT                   snake mambalgin-2 toxin."
FT                   /evidence="ECO:0000269|PubMed:24695733,
FT                   ECO:0000269|PubMed:26680001"
FT   MUTAGEN         352
FT                   /note="V->A: Moderate decrease in inhibition by the snake
FT                   mambalgin-2 toxin."
FT                   /evidence="ECO:0000269|PubMed:24695733"
FT   MUTAGEN         354
FT                   /note="K->A: No change in the shift of pH for both
FT                   activation and desensitization by the spider venom
FT                   psalmotoxin-1."
FT                   /evidence="ECO:0000269|PubMed:26248594"
FT   MUTAGEN         356
FT                   /note="Q->S: Moderate decrease in inhibition by the snake
FT                   mambalgin-2 toxin."
FT                   /evidence="ECO:0000269|PubMed:24695733"
FT   MUTAGEN         357
FT                   /note="E->N: Moderate decrease in inhibition by the snake
FT                   mambalgin-2 toxin."
FT                   /evidence="ECO:0000269|PubMed:24695733"
FT   MUTAGEN         425
FT                   /note="E->G: Reduction of Ca(2+) block. Loss of Ca(2+)
FT                   block; when associated with C-432."
FT                   /evidence="ECO:0000269|PubMed:15452199"
FT   MUTAGEN         431
FT                   /note="G->V,F: Constitutive channel activity."
FT                   /evidence="ECO:0000269|PubMed:9360943"
FT   MUTAGEN         432
FT                   /note="D->A: Reduction of Ca(2+) block."
FT                   /evidence="ECO:0000269|PubMed:15452199"
FT   MUTAGEN         432
FT                   /note="D->C: Reduction of Ca(2+) block. Loss of Ca(2+)
FT                   block; when associated with G-425."
FT                   /evidence="ECO:0000269|PubMed:15452199"
FT   MUTAGEN         436
FT                   /note="Q->N: No effect on Ca(2+) block."
FT                   /evidence="ECO:0000269|PubMed:15452199"
FT   CONFLICT        P55926-3:128
FT                   /note="T -> S (in Ref. 2; CAA07080)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   526 AA;  59641 MW;  5462A7786E2A1726 CRC64;
     MELKTEEEEV GGVQPVSIQA FASSSTLHGL AHIFSYERLS LKRALWALCF LGSLAVLLCV
     CTERVQYYFC YHHVTKLDEV AASQLTFPAV TLCNLNEFRF SQVSKNDLYH AGELLALLNN
     RYEIPDTQMA DEKQLEILQD KANFRSFKPK PFNMREFYDR AGHDIRDMLL SCHFRGEACS
     AEDFKVVFTR YGKCYTFNSG QDGRPRLKTM KGGTGNGLEI MLDIQQDEYL PVWGETDETS
     FEAGIKVQIH SQDEPPFIDQ LGFGVAPGFQ TFVSCQEQRL IYLPSPWGTC NAVTMDSDFF
     DSYSITACRI DCETRYLVEN CNCRMVHMPG DAPYCTPEQY KECADPALDF LVEKDQEYCV
     CEMPCNLTRY GKELSMVKIP SKASAKYLAK KFNKSEQYIG ENILVLDIFF EVLNYETIEQ
     KKAYEIAGLL GDIGGQMGLF IGASILTVLE LFDYAYEVIK HRLCRRGKCQ KEAKRSSADK
     GVALSLDDVK RHNPCESLRG HPAGMTYAAN ILPHHPARGT FEDFTC
//
